STOCK TITAN

Evogene - EVGN STOCK NEWS

Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.

Overview

Evogene (EVGN) is a pioneering computational biology company that leverages big data, artificial intelligence, and deep scientific insights to revolutionize the development of life-science-based products. Operating at the convergence of biotechnology and computational analytics, the company focuses on creating breakthrough solutions in agriculture, human health, and industrial applications. With its roots in advanced plant genomics research, Evogene integrates proprietary tech-engines and innovative predictive platforms to enhance seed traits and crop productivity.

Core Business Model and Technologies

At the heart of Evogene’s operations is its unique technology infrastructure composed of three distinct tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These platforms allow the company to systematically accelerate the discovery and development of novel products by targeting and optimizing key components such as microbes, small molecules, and genetic elements. This multi-engine approach not only reduces development time and costs but also increases the probability of success through sophisticated computational predictive biology.

Market Position and Strategic Collaborations

Evogene operates in the high-stakes arena of life sciences, where precision and innovation drive competitive advantage. The company addresses challenges in agricultural productivity by improving seed traits related to yield enhancement and stress tolerance. Its strategic collaborations with world-leading agricultural firms underscore its role as an unbiased, research-driven innovator in the sector. These partnerships facilitate the development of advanced ag-biological products, which include bio-inoculants and seed treatments that are designed to address both biotic and abiotic stresses in crops such as corn, soybean, wheat, and rice.

Diverse Subsidiary Operations

Evogene’s business model is diversified through its subsidiaries, each specializing in a niche area within the life sciences:

  • Lavie Bio Ltd. focuses on developing microbiome-based ag-biologicals and innovative bio-stimulant products using the MicroBoost AI tech-engine, enhancing crop vigor and stress tolerance.
  • Biomica Ltd. is dedicated to creating human microbiome-based therapeutics, harnessing the capabilities of its computational platforms to address complex medical challenges.
  • AgPlenus Ltd. utilizes ChemPass AI to design next-generation agricultural chemicals, supporting sustainable and effective crop protection measures.
  • Casterra Ag Ltd. commercializes elite castor seed varieties for biofuel and biopolymer production, making use of GeneRator AI to optimize plant genomics for industrial applications.

Technology-Driven Innovation and Operational Excellence

Evogene’s approach is deeply rooted in an advanced understanding of computational predictive biology. By leveraging its proprietary platforms and extensive datasets, the company is able to pinpoint genetic elements and microbial candidates that directly contribute to improved agricultural outputs. Its innovative use of artificial intelligence and big data analytics has allowed for rapid prototyping of solutions, which are then validated through extensive field trials and strategic partnerships. This methodical integration of technology into the research and development process affirms its commitment to reducing time-to-market while ensuring product efficacy and sustainability.

Competitive Landscape and Industry Significance

Within the rapidly evolving fields of computational biology and ag-biotechnology, Evogene distinguishes itself by combining deep domain expertise with technology-driven innovation. Unlike conventional approaches that rely on traditional trial-and-error methods, Evogene’s integrated strategy is designed to systematically inform product development, thereby minimizing risks while maximizing innovative output. Its successful collaborations with established industry players position Evogene as an authoritative resource in product design and predictive biology.

Key Industry Terminology and Concepts

The company’s operations are underpinned by several industry-specific terminologies that resonate with experts in the field:

  • Computational predictive biology: Utilizing algorithms and large data sets to model and predict biological outcomes.
  • Proprietary tech-engines: Engineered platforms such as MicroBoost AI, ChemPass AI, and GeneRator AI that incorporate multidisciplinary expertise.
  • Plant genomics: The scientific study of plants at the molecular level, which is critical to enhancing desirable seed traits.
  • Ag-biologicals and ag-chemicals: Products designed to improve crop resilience and productivity, often replacing traditional chemical inputs.

Conclusion

Evogene stands as an exemplar of how cutting-edge technology can drive advancements in the life-science sector. By integrating deep scientific research with sophisticated AI-driven platforms, the company not only improves agricultural outputs but also paves the way for innovative solutions in human therapeutics and industrial applications. Its diverse portfolio, strategic collaborations, and focus on continuous innovation have firmly established its reputation as a dynamic, forward-thinking entity in the competitive landscape of computational biology.

Rhea-AI Summary
Colors Farm, Evogene, and Ben-Gurion University have announced a collaboration to develop gene editing technology for crustaceans. The project aims to enhance traits such as growth rate, disease resistance, and environmental adaptation in giant freshwater prawn, white leg shrimp, and red swamp crayfish. The initiative has received a grant from the Israel Innovation Authority. The global shrimp market is predicted to reach US$88 billion by 2028 with a CAGR of 4.7%, while the crayfish market is expected to grow at a CAGR of 31.5% from 2024-2032. This collaboration aims to meet the rising demand for seafood and sustainable aquaculture practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
Rhea-AI Summary
Evogene provides an update to investors and stakeholders amidst the ongoing security situation in Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
none
-
Rhea-AI Summary
Casterra Ag Ltd. has announced the shipment of its first batch of high-yield, high-oil castor seeds valued at US$1 million. This is part of a framework agreement with a world-leading oil and gas company, with US$11.3M purchase orders. The seeds have a germination percentage rate of 90%, exceeding industry standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
Rhea-AI Summary
Evogene Ltd. announces financial results for Q2 2023, highlighting achievements and partnerships. Evogene secures $8.5M investment, receives purchase orders worth $11.3M, and closes $20M financing round for Biomica. Lavie Bio enters licensing agreement with Corteva for $5M upfront payment. AgPlenus appoints Dr. Adrian Percy to board of directors. Evogene reports consolidated cash of $33.9M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.23%
Tags
-
Rhea-AI Summary
Biomica Ltd., a clinical-stage biopharmaceutical company, has opened a second site at The Davidoff Cancer Center for its Phase I clinical trial of immuno-oncology drug candidate BMC128. The trial aims to assess the safety and tolerability of BMC128 in combination with Bristol Myers Squibb's Opdivo® for refractory patients with NSCLC, melanoma, or RCC. The Davidoff Center is a renowned comprehensive cancer center in Israel. Biomica's CEO expressed pride in the milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
Rhea-AI Summary
Evogene Ltd. (EVGN) to Release Q2 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
EVGN: Evogene Ltd. Announces Registered Direct Offering of 8,500,000 Ordinary Shares at $1.00 per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.71%
Tags
Rhea-AI Summary
Corteva Inc. (NYSE: CTVA) to receive exclusive rights to further develop and commercialize Lavie Bio's lead product candidates targeting fruit rot and powdery mildew. The agreement aims to address destructive diseases affecting vineyards, fruits, and vegetables, resulting in billions of dollars in annual losses globally. This collaboration demonstrates commitment to providing farmers with environmentally friendly, sustainable tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.71%
Tags
none

FAQ

What is the current stock price of Evogene (EVGN)?

The current stock price of Evogene (EVGN) is $0.97 as of April 18, 2025.

What is the market cap of Evogene (EVGN)?

The market cap of Evogene (EVGN) is approximately 7.1M.

What is Evogene's core business?

Evogene is a computational biology company that uses artificial intelligence and big data to develop innovative life-science products, including advanced solutions for agriculture and human health.

What proprietary technologies does Evogene use?

The company has developed three unique tech-engines—MicroBoost AI, ChemPass AI, and GeneRator AI—which are used to optimize the discovery and development of products based on microbes, small molecules, and genetic elements.

How does Evogene contribute to agricultural productivity?

Through its deep understanding of plant genomics and strategic partnerships, Evogene enhances seed traits, develops bio-inoculant products, and optimizes crop resistance to biotic and abiotic stresses.

What are Evogene's main market segments?

Evogene operates in multiple segments including agriculture, human therapeutics, and industrial applications, leveraging its AI-driven platforms to address diverse market needs.

Who are Evogene's key subsidiaries?

Evogene's portfolio includes Lavie Bio for ag-biologicals, Biomica for human microbiome-based therapeutics, AgPlenus for ag-chemicals, and Casterra Ag for advanced castor seed cultivation.

How does Evogene's technology reduce development time and cost?

By integrating computational predictive biology with big data analytics, Evogene’s platforms streamline product discovery and optimization, significantly cutting down on both time and cost during development.

What differentiates Evogene from other biotech companies?

Evogene’s unique integration of AI-driven tech-engines with deep scientific expertise in plant genomics and life sciences sets it apart, enabling more accurate predictions and faster development cycles.

How does Evogene maintain its competitive edge in the industry?

Through strategic collaborations, continuous innovation, and a diversified portfolio of subsidiaries, Evogene positions itself as an authoritative and trusted partner in the development of life-science products.
Evogene

Nasdaq:EVGN

EVGN Rankings

EVGN Stock Data

7.13M
6.59M
1.56%
7.68%
0.51%
Biotechnology
Healthcare
Link
Israel
Rehovot